Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1951 AL 1965

Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis

Wu X, Tang KF, Li Y, Xiong YY, Shen L, Wei ZY, Zhou KJ, Niu JM, Han X, Yang L, Feng GY, He L, Qin SY.

Parkinsonism Relat Disord. 2012 Jul;18(6):722-30. doi: 10.1016/j.parkreldis.2012.04.013. Epub 2012 May 8.

Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease

Koppula S, Kumar H, Kim IS, Choi DK.

Mediators Inflamm. 2012;2012:823902. doi: 10.1155/2012/823902. Epub 2012 Apr 22.

Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease

Lee BD, Dawson VL, Dawson TM.

Trends Pharmacol Sci. 2012 Jul;33(7):365-73. doi: 10.1016/j.tips.2012.04.001. Epub 2012 May 9.

PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS)

Pediatric and Congenital Electrophysiology Society (PACES); Heart Rhythm Society (HRS); American College of Cardiology Foundation (ACCF); American Heart Association (AHA); American Academy of Pediatrics (AAP); Canadian Heart Rhythm Society (CHRS); Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE.

Heart Rhythm. 2012 Jun;9(6):1006-24. doi: 10.1016/j.hrthm.2012.03.050. Epub 2012 May 10.

Urate in Parkinson's disease: more than a biomarker?

Chen X, Wu G, Schwarzschild MA.

Curr Neurol Neurosci Rep. 2012 Aug;12(4):367-75. doi: 10.1007/s11910-012-0282-7.

Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?

Barnum CJ, Tansey MG.

Curr Neurol Neurosci Rep. 2012 Aug;12(4):350-8. doi: 10.1007/s11910-012-0283-6.

HMGB1 in development and diseases of the central nervous system

Fang P, Schachner M, Shen YQ.

Mol Neurobiol. 2012 Jun;45(3):499-506. doi: 10.1007/s12035-012-8264-y. Epub 2012 May 13.

Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors

Surace MJ, Block ML.

Cell Mol Life Sci. 2012 Jul;69(14):2409-27. doi: 10.1007/s00018-012-1015-4. Epub 2012 May 13.

Current status of tyrosine hydroxylase in management of Parkinson's disease

Feve AP.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):450-5. doi: 10.2174/187152712800792910.

A brief overview of tyrosine hydroxylase and α-synuclein in the Parkinsonian brain

Khan W, Priyadarshini M, Zakai HA, Kamal MA, Alam Q.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):456-62. doi: 10.2174/187152712800792929.

Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase

Priyadarshini M, Kamal MA, Greig NH, Reale M, Abuzenadah AM, Chaudhary AG, Damanhouri GA.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):482-9. doi: 10.2174/187152712800792767.

Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease

Bademci G, Vance JM, Wang L.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):469-81. doi: 10.2174/187152712800792866.

Editorial: Status of tyrosine hydroxylase in the healthy and Parkinson's brain

Kamal MA.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):336-9. doi: 10.2174/187152712800792857.

What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy

Jain S, Goldstein DS.

Neurobiol Dis. 2012 Jun;46(3):505-7. doi: 10.1016/j.nbd.2012.04.013.

Olfactory dysfunction in Parkinson disease

Doty RL.

Nat Rev Neurol. 2012 May 15;8(6):329-39. doi: 10.1038/nrneurol.2012.80.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias